Mycophenolic Acid Shortage Update: What Patients Need to Know in 2026

For transplant patients who take mycophenolic acid (Myfortic) or mycophenolate mofetil (CellCept) every day, any news of drug shortages is understandably alarming. This medication is not optional—it's what keeps your immune system from attacking your transplanted organ. Here's an honest, up-to-date look at the availability situation in 2026.

Current Status: Is There a Mycophenolic Acid Shortage in 2026?

As of 2026, there is no active FDA-declared nationwide shortage of mycophenolate mofetil (the most commonly prescribed form, sold as CellCept in brand and available widely as a generic). Generic mycophenolate mofetil is manufactured by many companies including Teva, Sandoz, Mylan (now Viatris), Hikma, Accord, and Ascend, providing robust supply redundancy.

However, mycophenolate sodium delayed-release tablets (the generic of Myfortic) have experienced intermittent ASHP-tracked shortages from specific manufacturers. During past disruptions, some generic makers (including Apotex and Major) were on backorder, while Mylan's generics and brand-name Myfortic from Novartis remained available. Currently, multiple generics are available through most pharmacy distribution channels.

History of Mycophenolate Shortages

Mycophenolate mofetil itself has had a relatively stable supply history compared to many other specialty medications. When disruptions have occurred, they have typically been:

Manufacturer-specific: One manufacturer goes on backorder while others maintain supply. This creates localized gaps depending on which manufacturer your pharmacy sources from.

The 2020 ASHP shortage of mycophenolate sodium delayed-release tablets affected Apotex and Major's 30-count and 100-count bottle sizes, while Mylan products remained available.

COVID-19-era supply chain disruptions in 2020–2021 had a minor impact on the broader immunosuppressant market but were less severe than shortages in other drug categories.

Why Demand for Mycophenolate Continues to Grow

Even in the absence of an active shortage, finding mycophenolate at a specific pharmacy can occasionally be challenging because demand is increasing. The United States performed over 46,000 organ transplants in 2023 alone—an 8.7% increase over 2022—meaning a growing number of patients need lifelong immunosuppression therapy. This rising demand puts pressure on pharmacy stocking patterns.

Additionally, mycophenolate is increasingly used off-label for autoimmune conditions like lupus nephritis, IgA nephropathy, vasculitis, pemphigus vulgaris, and pulmonary fibrosis—further increasing the patient population using these medications.

What Makes Mycophenolate Sodium Delayed-Release More Vulnerable to Shortages?

Mycophenolate sodium delayed-release tablets (Myfortic generic) face a different availability landscape than mycophenolate mofetil because:

Fewer generic manufacturers produce this formulation compared to mycophenolate mofetil

It is FDA-approved only for kidney transplant prevention (not heart or liver), limiting its overall market volume

Fewer competing manufacturers means one manufacturer's backorder creates a larger gap in supply

What Should Patients Do Right Now?

Even without an active shortage, proactive steps protect you from being caught off guard:

Fill prescriptions 5–7 days early to maintain a small buffer supply.

Request 90-day fills if your insurance allows, to reduce how often you need to source the medication.

Know your pharmacy's supplier: Ask your pharmacist which manufacturer's product they typically stock. If that manufacturer has issues, you'll know sooner.

Have a backup pharmacy: Know which other pharmacies in your area also carry your specific formulation.

Use medfinder:

medfinder calls pharmacies near you to check which ones have your specific medication in stock, so you don't have to spend time on hold with multiple pharmacies.

Bottom Line

Mycophenolate mofetil is not in an active nationwide shortage in 2026, and mycophenolate sodium availability has improved from past disruption periods. Still, localized stocking gaps can and do occur. Plan ahead, know your options, and if your pharmacy can't fill your prescription, see our guide on alternatives to mycophenolic acid and contact your transplant team immediately.